- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Surya Singh, MD, Explains the Buy-and-Bill Model
Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, says the buy-and-bill model is most typically applied to the provider space, and more specifically to physicians' offices.
Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, says the buy-and-bill model is most typically applied to the provider space, and more specifically to physicians’ offices. It describes the supply chain for infusion medications, predominately self-injectables that require clinical monitoring, and that are administered or sourced through practitioners.
In this model, buying refers to the procurement of the drugs by the practice, and the billing refers to the bill sent directly to payers.
“There’s been a growth in the number of hospital outpatient centers that source drugs and then bill payers directly through their contracts,” says Dr Singh; “And that’s on the rise given the acquisitions of physician practices in oncology and in other relevant specialties.”
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
